Wells Fargo's 'Value Equity List' – Stocks With Potential That Trade at a Discount
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Cantor Fitzgerald Reiterates Neutral on Gilead Sciences, Maintains $70 Price Target
Gilead Sciences Analyst Ratings
Kyverna Therapeutics Names Warner Biddle CEO
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $95
Jefferies analyst Michael Yee maintains $Gilead Sciences(GILD.US)$ with a buy rating, and maintains the target price at $95.According to TipRanks data, the analyst has a success rate of 43.3% and a
Jefferies Remains a Buy on Gilead Sciences (GILD)
This 'Forgotten Child' Is One of the Best Biotech Plays: Analyst
Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention
Hold Rating on Gilead Sciences Amid Lenacapavir's Promise and Market Uncertainties
Should You Be Worried About Gilead Sciences, Inc.'s (NASDAQ:GILD) 5.7% Return On Equity?
Insider Sale: Johanna Mercier Sells 29,357 Shares of Gilead Sciences Inc (GILD)
Gilead Sciences Insider Sold Shares Worth $2,459,577, According to a Recent SEC Filing
Mizuho Securities Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $90
Mizuho Securities analyst Salim Syed maintains $Gilead Sciences(GILD.US)$ with a buy rating, and maintains the target price at $90.According to TipRanks data, the analyst has a success rate of 39.4%
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Daily short sale tracking: Warner Bros Discovery's short volume increased by 4 million, with a short sale ratio of 16%
Warner Bros Discovery(WBD.US) ranked top of the list had the largest change in short volume (4.21 million shares), and the short volume ratio of Canadian Imperial Bank of Commerce(CM.US) reached 63.67%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Marengo Therapeutics Enters Clinical Study Collaboration And Supply Agreement With Gilead Sciences
Express News | Marengo Therapeutics: Under Agreement, Gilead Will Provide Trodelvy to Marengo
Marengo Therapeutics Announces Clinical Study Collaboration With Gilead Sciences to Evaluate Invikafusp Alfa (STAR0602) and Trodelvy in Both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers
J.P. Morgan Maintains Gilead Sciences(GILD.US) With Buy Rating
J.P. Morgan analyst Chris Schott maintains $Gilead Sciences(GILD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 54.0% and a total average return of 2.5% over